ASCO 2021 - Lung Cancer

Findings of the prospective community-based observational NILE study support the use of cfDNA to identify actionable genomic alterations in newly diagnosed patients with advanced lung adenocarcinoma. Read More ›

The LC-SCRUM-Asia project analysis indicated that utilization of rapid multigene assays in patients with advanced non–small-cell lung cancer (NSCLC) was associated with short turnaround times and high success rates compared with a targeted assay. Read More ›

Provider adherence to National Comprehensive Cancer Network recommendations and implementation of an automated regimen-level prior authorization is associated with lower cost and more efficient oncology care in patients with non–small-cell lung cancer. Read More ›

The majority of progressing stage IV non–small-cell lung cancer patients with development of resistance to targeted therapies benefit from repeat molecular profiling to detect actionable resistance mechanisms and facilitate clinical trial enrollment. Read More ›

A mobile computerized tomographic lung screening program detected a high number of incidental concurrent disease findings in a rural underserved high-risk population of heavy smokers. Read More ›

Analysis of the National Cancer Database indicates that a lower proportion of black patients with locally advanced, stage III, non–small-cell lung cancer (NSCLC) receive concurrent chemotherapy plus radiotherapy compared with white patients. Read More ›

Significant racial disparities exist among lung cancer survivors in receipt of surveillance scans, guidance about follow-up care, and smoking cessation. Read More ›

Atezolizumab in patients with resected stage II/IIIA non–small-cell lung cancer (NSCLC) extends disease-free survival compared with best supportive care after receiving adjuvant chemotherapy. Read More ›

Findings from KEYNOTE-598 detected no difference in health-related quality of life or time to true deterioration in lung cancer symptoms comparing treatment with pembrolizumab + ipilimumab versus pembrolizumab + placebo in patients with previously untreated metastatic non–small-cell lung cancer (NSCLC) with PD-L1 tumor proportion score ≥50%. Read More ›

Patients with pretreated KRAS p.G12C–mutated non–small-cell lung cancer (NSCLC) treated with sotorasib improved or maintained global health status/quality of life, physical functioning, and the severity of key lung cancer–related symptoms. Read More ›

Page 1 of 2

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to receive the free OPM print publications or weekly e‑Newsletter.

I'd like to receive: